Ovarian cancer is one of three female genital malignant tumors, whichaccounts for 2.4% ~ 2.5% in common female malignant tumors. One source of themalignant epithelial ovarian cancer accounts for 85-90%. About 70% of patientsare found in the late, 5-year survival rate inⅠ,Ⅱperiod of ovarian cancer is80% ~ 90%,Ⅲ,Ⅳperiod only 20% ~ 30%, At present, the use of surgery,chemotherapy, radiotherapy, biological treatment by means of a comprehensivetreatment of ovarian cancer, chemotherapy improvement and application of newchemotherapy drugs have greatly improved the survival rate of ovarian cancer, buttreatment is still unsatisfactory. Thus, to explore new means of early diagnosisand treatment measures of ovarian cancer are particularly important.Somatostatin is the human body has a broad biological activity of a cyclicpeptide hormone, with the cell membrane somatostatin receptor-bindingspecificity, to play its biological activity. In recent years, animal experiments andhuman cell lines outside of the study showed that somatostatin have inhibited cellgrowth, anti-tumor proliferation, induction of apoptosis and regulation of immuneactivity, such as the role of immune cells. Therefore, with the anti-tumormechanism of somatostatin\'s with a new generation of further research anddevelopment of somatostatin analogues, somatostatin receptor allows to treatmalignant tumors has the potential to become a promising candidate gene. Somatostatin (somatostatin, SST) widely exists in the brain, pituitary, pancreas,gastrointestinal tract, adrenal gland, thyroid, kidney and immune system, theendocrine cells from the special-D cell synthesis and release. Its target cellmembrane through specific somatostatin receptor (somatostatin receptor, SSTR)binding, and to play its biological activity, can inhibit nearly all internal andexternal secretory function of internal organs and can reduce the blood flow,inhibiting smooth muscle contraction, on the the activity of immune cells alsohave a certain extent. To compared with SST, SSTA selective high, long half-life,the role of strong, safe and convenient to use and so on. Been widely usedclinically, efficacy, and a representative of the somatostatin analogues are asfollows: octreotide (octreotide), lanreotide (lanreotide), cutting & P peptide(vapreotide) and so on, has been widely used in gastrointestinal bleeding,pancreatitis , gastrointestinal fistula, gastrointestinal and pancreatic endocrinetumors, such as the treatment of solid tumors. In addition, SSTR-mediatedinhibition of SS tumor cells produce growth, anti-tumor cell proliferation andinduced apoptosis of tumor cells, more and more attention.This experiment by using immunohistochemistry method of SSTR1 in 60cases of ovarian specimens, including 33 cases of malignant expression andclinicopathological parameters of ovarian cancer relations. The experimental datausing statistical software SPSS13.0 simple statistical analysis, statistical analysisusing t tests, multiple sets of samples were compared using a number of one-wayANOVA, when the p value of less than 0.05, considered statistically significant. The experimental results showed that: SSTR1 protein in tissues of eachgroup have different levels of expression, and expression was mainly located inthe serosa cells, in interstitial cells in each group did not express the basic. In theovarian cancer group SSTR1 expression was significantly higher than that innormal ovary group, there was a significant difference (P = 0.0231); in theexpression of ovarian benign tumor group than in normal ovarian group, but didnot reach statistical levels, no significant difference (P> 0.05). SSTR1 expressionand tumor differentiation and clinical stage (P  0.05). Of SSTR1 in epithelial ovarian cancer tissues and its relationshipwith clinicopathological features of the relationship between, suggesting that highexpression of SSTR1 may be related to the occurrence and development ofovarian cancer and is closely related to malignant transformation. Possible forclinical diagnosis and treatment of ovarian cancer to provide new ideas. If theabove theory is applied to the clinical, treatment may open up a new approach toovarian cancer.Concluded that the fully-mechanized: 1, SSTR1 protein in epithelial ovariancarcinoma was significantly higher than normal ovarian group. High expression ofSSTR1 in ovarian cancer may play an important role in development. 2, SSTR1expression and clinical stage, degree of differentiation (P  0.05). SSTR1 that may be related to the occurrence of ovarian development and is closely related to the degree of malignancy. 3, throughthe exploration of SSTR1 protein in the occurrence and development of cervicalcancer in the important role may be for clinical diagnosis and treatment of ovariancancer to provide new ideas. If the above theory is applied to the clinical,treatment may open up a new approach to ovarian cancer.SSTR1 protein in ovarian cancer is highly expressed in the tips of theoccurrence and development of ovarian cancer may play an important role. Thisresult for the future application of receptor imaging diagnosis of ovarian cancer,the development of receptor subtype specific somatostatin analogues in thetreatment of ovarian cancer provides a theoretical basis. SSTR1 expression inovarian cancer and clinical stage, degree of differentiation, suggesting that SS andits analogues has been the basis for the treatment of ovarian cancer and possible.SST analogue drugs can be combined with chemotherapy drugs, through selectivearterial perfusion regional or intra-abdominal administration continued to improvethe SST and its analogues in tumor tissues of the drug concentration, the betterable to inhibit the growth of ovarian cancer. Might be more helpful to SST and itsanalogues play the role of anti-tumor.